Adam Savitz - Feb 1, 2024 Form 3 Insider Report for Alto Neuroscience, Inc. (ANRO)

Role: Chief Medical Officer
Signature: /s/ Erin R. McQuade, Attorney-in-Fact
Stock symbol: ANRO
Transactions as of: Feb 1, 2024
Transactions value $: $0
Form type: 3
Date filed: 2/1/2024, 06:45 PM
Next filing: Feb 7, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ANRO	Series B Preferred Stock							Feb 1, 2024	Common Stock	7.85K		By Trust	F1, F2
holding	ANRO	Employee Stock Option (Right to Buy)							Feb 1, 2024	Common Stock	135K	$2.32	Direct	F3
holding	ANRO	Employee Stock Option (Right to Buy)							Feb 1, 2024	Common Stock	22.5K	$6.23	Direct	F4
holding	ANRO	Employee Stock Option (Right to Buy)							Feb 1, 2024	Common Stock	33K	$6.23	Direct	F5
holding	ANRO	Employee Stock Option (Right to Buy)							Feb 1, 2024	Common Stock	124K	$5.30	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series B Preferred Stock is convertible at any time, at the holder's election, and will automatically convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis into the number of shares of Common Stock shown in column 3 and has no expiration date.
F2	The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the "Friedman Trust"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust.
F3	25% of the shares underlying the option vested on July 6, 2022, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F4	The shares subject to the option are fully vested and exercisable.
F5	25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F6	25% of the shares underlying the option vested on December 20, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.